AU2017247880B2 - Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion - Google Patents

Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion Download PDF

Info

Publication number
AU2017247880B2
AU2017247880B2 AU2017247880A AU2017247880A AU2017247880B2 AU 2017247880 B2 AU2017247880 B2 AU 2017247880B2 AU 2017247880 A AU2017247880 A AU 2017247880A AU 2017247880 A AU2017247880 A AU 2017247880A AU 2017247880 B2 AU2017247880 B2 AU 2017247880B2
Authority
AU
Australia
Prior art keywords
antibody
acd25
tumour
days
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017247880A
Other languages
English (en)
Other versions
AU2017247880A1 (en
Inventor
Karl PEGGS
Sergio Quezada
Frederick Arce VARGAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Publication of AU2017247880A1 publication Critical patent/AU2017247880A1/en
Application granted granted Critical
Publication of AU2017247880B2 publication Critical patent/AU2017247880B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017247880A 2016-04-07 2017-03-17 Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion Active AU2017247880B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1605947.9 2016-04-07
GB201605947 2016-04-07
PCT/EP2017/056469 WO2017174331A1 (en) 2016-04-07 2017-03-17 Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion

Publications (2)

Publication Number Publication Date
AU2017247880A1 AU2017247880A1 (en) 2018-11-15
AU2017247880B2 true AU2017247880B2 (en) 2024-07-11

Family

ID=58358618

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017247880A Active AU2017247880B2 (en) 2016-04-07 2017-03-17 Anti CD25 FC gamma receptor bispecific antibodies for tumor specific cell depletion

Country Status (15)

Country Link
US (2) US20190135925A1 (OSRAM)
EP (1) EP3440109B1 (OSRAM)
JP (1) JP7325959B2 (OSRAM)
KR (2) KR20220032642A (OSRAM)
CN (1) CN109476739A (OSRAM)
AU (1) AU2017247880B2 (OSRAM)
BR (1) BR112018070636A2 (OSRAM)
CA (1) CA3020204A1 (OSRAM)
CL (2) CL2018002828A1 (OSRAM)
ES (1) ES3046543T3 (OSRAM)
IL (1) IL262129B2 (OSRAM)
MX (1) MX2018012319A (OSRAM)
PL (1) PL3440109T3 (OSRAM)
RU (1) RU2759970C2 (OSRAM)
WO (1) WO2017174331A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011592A1 (en) 2015-07-13 2017-01-19 Modular Genetics, Inc. Generation of acyl alcohols
RU2759970C2 (ru) 2016-04-07 2021-11-19 Кансер Ресёрч Текнолоджи Лимитед БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
GB201712032D0 (en) 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
CN120617499A (zh) * 2018-01-10 2025-09-12 生物发明国际公司 抗体的新型组合和用途
BR112020016374A2 (pt) * 2018-02-13 2020-12-15 Precision Biologics, Inc. Métodos e composições para direcionar células treg
SG11202008733YA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
EP3566718A1 (en) * 2018-05-07 2019-11-13 Universitätsmedizin der Johannes Gutenberg-Universität Mainz A pharmazeutical combination (treg depleting agent, checkpoint inhibitor, tlr9 agonist) for use in the treatment of cancer
EP3830129A4 (en) * 2018-07-30 2022-05-04 Invenra, Inc. MULTISPECIFIC TREG-BINDING MOLECULES
CN113272330B (zh) * 2019-03-02 2024-07-26 南通壹宸生物医药科技有限公司 一种双特异抗体
WO2021145946A1 (en) * 2020-01-13 2021-07-22 Invenra Inc. Multispecific treg binding molecules
EP4103611B1 (en) * 2020-02-13 2024-03-27 UCB Biopharma SRL Bispecific antibodies binding hvem and cd9
EP4151655A1 (en) 2020-05-14 2023-03-22 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-cd25 antibodies, antigen-binding fragments thereof, and medical uses thereof
EP4243860A4 (en) * 2020-11-13 2024-10-16 iBio, Inc. ANTI-CD25 ANTIBODIES
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
US20240352136A1 (en) 2021-09-02 2024-10-24 Hoffmann-La Roche Inc. Antibodies for the treatment of aml
TW202336033A (zh) * 2022-03-07 2023-09-16 瑞典商生物創新國際有限公司 抗體之新穎組合及用途
WO2023208990A1 (en) 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
KR20240113400A (ko) * 2023-01-11 2024-07-22 한국과학기술원 종양 내 Treg의 바이오마커를 포함하는 진단용 조성물 및 약학 조성물
EP4662238A1 (en) 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof
CN120917143A (zh) 2023-03-29 2025-11-07 第一三共株式会社 抗cd25抗体及抗cd25抗体-药物偶联物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0316282B8 (pt) * 2002-11-15 2021-05-25 Genmab As anticorpo humano isolado monoclonal, composição, imunoconjugado, molécula biespecífica ou multiespecífica, método e conjunto de diagnóstico para detectar a presença de antígeno cd25 ou uma célula que expressa cd25, e, vetor de expressão
GB0507696D0 (en) 2005-04-15 2005-05-25 Novartis Ag Organic compounds
AU2007342338A1 (en) * 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
JPWO2010030002A1 (ja) 2008-09-12 2012-02-02 国立大学法人三重大学 外来性ｇｉｔｒリガンド発現細胞
RU2759970C2 (ru) 2016-04-07 2021-11-19 Кансер Ресёрч Текнолоджи Лимитед БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
SG11202008733YA (en) * 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
WO2023208990A1 (en) * 2022-04-26 2023-11-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014145907A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Targeting t cells with heterodimeric proteins

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Andrew J. Rech and Robert H. Vonderheide. "Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells", Cancer Vaccines: Ann. N.Y. Acad. Sci. 1174: 99–106 (2009). *
FURNESS ANDREW J S ET AL: TRENDS IN IMMUNOLOGY, vol. 35, no. 7, July 2014 (2014-07-01), pages 290 - 298. *
Joannes F.M. Jacobs et al. "Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients", Clin Cancer Res; 16(20) October 15, 2010. *
Michael J. Flynn and John A. Hartley. "The emerging role of anti-CD25 directed therapies as both immune modulators and targeted agents in cancer", British Journal of Haematology, 2017, 179, 20–35. *
Mikayel Mkrtichyan et al. "Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms", Eur J Immunol. 2011 October ; 41(10): 2977–2986. doi:10.1002/eji.201141639. *
Nimmerjahn F, Gordan S, Lux A. Trends Immunol. 2015 Jun;36(6):325-36. *
Pierre Bruhns and Friederike Jonsson, "Mouse and human FcR effector functions", Immunological Reviews 2015, Vol. 268: 25–51. *
SUTMULLER, R. PM et al., J. Exp. Med. Volume 194, Number 6, September 17, 2001 823–832. *
YU, P. et al. "Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model", PNAS, April 17, 2012, vol. 109, no. 16, Pg 6187–6192. *

Also Published As

Publication number Publication date
US20230265200A1 (en) 2023-08-24
IL262129B1 (en) 2025-03-01
IL262129A (en) 2018-11-29
WO2017174331A1 (en) 2017-10-12
CL2018002828A1 (es) 2019-03-08
CL2019003498A1 (es) 2020-05-29
EP3440109B1 (en) 2025-07-23
EP3440109A1 (en) 2019-02-13
PL3440109T3 (pl) 2025-12-01
BR112018070636A2 (pt) 2019-02-05
RU2018135247A3 (OSRAM) 2021-01-20
ES3046543T3 (en) 2025-12-02
EP3440109C0 (en) 2025-07-23
JP7325959B2 (ja) 2023-08-15
KR20220032642A (ko) 2022-03-15
RU2018135247A (ru) 2020-05-12
CN109476739A (zh) 2019-03-15
US20190135925A1 (en) 2019-05-09
CA3020204A1 (en) 2017-10-12
JP2019513725A (ja) 2019-05-30
MX2018012319A (es) 2019-06-06
IL262129B2 (en) 2025-07-01
RU2759970C2 (ru) 2021-11-19
AU2017247880A1 (en) 2018-11-15
KR20190017735A (ko) 2019-02-20

Similar Documents

Publication Publication Date Title
US20230265200A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
AU2018233976B2 (en) Fc-optimized anti-CD25 for tumour specific cell depletion
JP7225135B2 (ja) 腫瘍特異的細胞枯渇のための化合物及び方法
WO2022003156A1 (en) Ccr8 non-blocking binders
US20230058227A1 (en) Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
WO2016011069A1 (en) Medical uses of cd38 agonists (antibodies)
KR20220025739A (ko) T-세포 활성화를 위한 항체
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
HK40018012A (en) Compounds and methods for tumour-specific cell depletion
HK40016585B (zh) 用於肿瘤特异性细胞消耗的fc优化的抗cd25
HK40016585A (en) Fc-optimized anti-cd25 for tumor specific cell depletion

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ QUEZADA, SERGIO; PEGGS, KARL AND VARGAS, FREDERICK ARCE

FGA Letters patent sealed or granted (standard patent)